[Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].
The effects of i.v. cytomegalovirus (CMV) immunoglobulin given for prophylaxis of CMV infections in recipients of allogeneic and autologous marrow transplants were evaluated in a randomized trial: 60 patients were randomly assigned to receive (30 patients) or not to receive (30 patients) CMV immunoglobulin for a period of 90 days after transplantation. As to the allografted patients, the cumulative incidence of asymptomatic and symptomatic CMV infections was significantly reduced in the CMV immunoglobulin-treated group as compared to the control group (56.5% versus 92.9%, P less than 0.05). No other statistically significant effect of CMV immunoglobulin could be found. In particular, the incidence of symptomatic CMV infections (including interstitial pneumonia), the mean delay of post-transplant viraemia and haematopoietic recovery were similar in the control and CMV immunoglobulin-treated groups. We conclude that prophylactic CMV immunoglobulin administration, as designed in our study, is no more than marginally effective and cannot be recommended without additional trials.
Bordigoni
P
P
Unité de greffe médullaire, Hôpital d'Enfants, Centre Hospitalier Universitaire de Nancy, France.
Janot
C
C
Aymard
J P
JP
Witz
F
F
Bené
M C
MC
Legras
B
B
Schoonemann
F
F
Olive
D
D
Streiff
F
F
D000914:Antibodies, Viral / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D006801:Humans; D007116:Immunization, Passive; D007275:Injections, Intravenous; D011897:Random Allocation
D000914:Antibodies, Viral
Evaluation clinique et biologique du rôle prophylactique des immunoglobulines spécifiques anti-cytomégalovirus dans les greffes médullaires. Etude randomisée de 60 patients.